Bruce  Booth net worth and biography

Bruce Booth Biography and Net Worth

Director of Kymera Therapeutics
Bruce Booth is a partner and focuses on the discovery and development of novel medicines and therapeutic platforms.

Bruce is currently chairman of Arkuda Therapeutics, AvroBio (NASDAQ:AVRO), Hotspot Therapeutics, Kymera Therapeutics (NASDAQ:KYMR), Nimbus Therapeutics, and Vigil Neuroscience. He also serves on the board of Magenta Therapeutics (NASDAQ:MGTA) and several seed stage companies. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics (acquired by Bial), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), and a number of other ventures.

Bruce serves or has served as an advisor in various capacities to Takeda, UCB, the Gates Foundation, and Dana Farber’s Binney Street Capital advisory board. He also serves on the boards of the Pennsylvania State Research Foundation, which helps with technology transfer, and New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes.

Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Bruce enjoys running, skiing, hiking, and fly fishing. He lives in Wellesley, MA and has three wonderful kids.

What is Bruce Booth's net worth?

The estimated net worth of Bruce Booth is at least $30.40 million as of July 9th, 2024. Dr. Booth owns 723,246 shares of Kymera Therapeutics stock worth more than $30,398,029 as of July 22nd. This net worth evaluation does not reflect any other assets that Dr. Booth may own. Additionally, Dr. Booth receives an annual salary of $75,000.00 as Director at Kymera Therapeutics. Learn More about Bruce Booth's net worth.

How old is Bruce Booth?

Dr. Booth is currently 50 years old. There are 4 older executives and no younger executives at Kymera Therapeutics. The oldest executive at Kymera Therapeutics is Ms. Ellen V. Chiniara Esq., J.D., Chief Legal Officer & Corporate Secretary, who is 65 years old. Learn More on Bruce Booth's age.

What is Bruce Booth's salary?

As the Director of Kymera Therapeutics, Inc., Dr. Booth earns $75,000.00 per year. There are 4 executives that earn more than Dr. Booth. The highest earning executive at Kymera Therapeutics is Dr. Nello Mainolfi M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,080,000.00 per year. Learn More on Bruce Booth's salary.

How do I contact Bruce Booth?

The corporate mailing address for Dr. Booth and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]. Learn More on Bruce Booth's contact information.

Has Bruce Booth been buying or selling shares of Kymera Therapeutics?

Over the course of the past ninety days, Bruce Booth has sold $17,345,811.60 in Kymera Therapeutics stock. Most recently, Bruce Booth sold 453,960 shares of the business's stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a transaction totalling $17,345,811.60. Following the completion of the sale, the director now directly owns 723,246 shares of the company's stock, valued at $27,635,229.66. Learn More on Bruce Booth's trading history.

Who are Kymera Therapeutics' active insiders?

Kymera Therapeutics' insider roster includes Bruce Booth (Director), Richard Chesworth (Insider), Jared Gollob (Insider), Bruce Jacobs (CFO), and Nello Mainolfi (CEO). Learn More on Kymera Therapeutics' active insiders.

Are insiders buying or selling shares of Kymera Therapeutics?

In the last twelve months, Kymera Therapeutics insiders bought shares 1 times. They purchased a total of 216,406 shares worth more than $2,518,965.84. In the last twelve months, insiders at the sold shares 14 times. They sold a total of 989,691 shares worth more than $39,279,044.03. The most recent insider tranaction occured on July, 16th when insider Jared Gollob sold 23,145 shares worth more than $1,060,272.45. Insiders at Kymera Therapeutics own 15.8% of the company. Learn More about insider trades at Kymera Therapeutics.

Information on this page was last updated on 7/16/2024.

Bruce Booth Insider Trading History at Kymera Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/9/2024Sell453,960$38.21$17,345,811.60723,246View SEC Filing Icon  
6/12/2024Sell16,740$35.45$593,433.00803,792View SEC Filing Icon  
3/15/2024Sell71,764$40.46$2,903,571.44806,697View SEC Filing Icon  
3/13/2024Sell139,255$42.23$5,880,738.65828,830View SEC Filing Icon  
3/11/2024Sell51,184$42.85$2,193,234.40881,266View SEC Filing Icon  
12/14/2022Sell378,966$31.37$11,888,163.42918,528View SEC Filing Icon  
11/2/2022Sell123,619$30.02$3,711,042.381,022,502View SEC Filing Icon  
10/31/2022Sell120,622$30.23$3,646,403.061,066,388View SEC Filing Icon  
10/28/2022Sell91,050$30.00$2,731,500.001,092,771View SEC Filing Icon  
8/11/2021Sell242,133$61.00$14,770,113.00View SEC Filing Icon  
3/12/2021Sell229,350$56.50$12,958,275.00View SEC Filing Icon  
See Full Table

Bruce Booth Buying and Selling Activity at Kymera Therapeutics

This chart shows Bruce Booth's buying and selling at Kymera Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kymera Therapeutics Company Overview

Kymera Therapeutics logo
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $42.47
Low: $41.54
High: $43.48

50 Day Range

MA: $34.65
Low: $29.85
High: $48.49

2 Week Range

Now: $42.47
Low: $9.60
High: $48.70

Volume

727,835 shs

Average Volume

687,813 shs

Market Capitalization

$2.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.22